SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia

Ashley Pinchinat; Sumit Gupta; Stacy L. Cooper; Rachel E. Rau

doi:10.1016/j.clml.2022.12.011

SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia

Ashley Pinchinat, Sumit Gupta, Stacy L. Cooper, Rachel E. Rau

School of Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Blinatumomab is a CD19 targeting bi-specific T-cell engager antibody construct developed for the treatment of CD19 expressing B-cell malignancies. Numerous adult and pediatric B-ALL clinical trials have demonstrated blinatumomab's efficacy in the relapse setting as well as in patients with residual disease after upfront chemotherapy. The safety profile of blinatumomab is also favorable, making it a feasible option for most patients. Several key questions remain, including the role of blinatumomab as a replacement for toxic elements of standard chemotherapy regimens in the upfront setting, its role as a bridge to hematopoietic stem cell transplantation, or whether previous blinatumomab impacts the efficacy of subsequent CAR-T cell therapy.

Original language	English (US)
Pages (from-to)	159-167
Number of pages	9
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/j.clml.2022.12.011
State	Published - Mar 2023

Keywords

B-ALL
Immunotherapy
Minimal residual disease

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2022.12.011

Cite this

@article{7b0b2a5017434c8d9fd223ba4a75bfda,

title = "SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia",

abstract = "Blinatumomab is a CD19 targeting bi-specific T-cell engager antibody construct developed for the treatment of CD19 expressing B-cell malignancies. Numerous adult and pediatric B-ALL clinical trials have demonstrated blinatumomab's efficacy in the relapse setting as well as in patients with residual disease after upfront chemotherapy. The safety profile of blinatumomab is also favorable, making it a feasible option for most patients. Several key questions remain, including the role of blinatumomab as a replacement for toxic elements of standard chemotherapy regimens in the upfront setting, its role as a bridge to hematopoietic stem cell transplantation, or whether previous blinatumomab impacts the efficacy of subsequent CAR-T cell therapy.",

keywords = "B-ALL, Immunotherapy, Minimal residual disease",

author = "Ashley Pinchinat and Sumit Gupta and Cooper, {Stacy L.} and Rau, {Rachel E.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2023",

month = mar,

doi = "10.1016/j.clml.2022.12.011",

language = "English (US)",

volume = "23",

pages = "159--167",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "3",

}

TY - JOUR

T1 - SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia

AU - Pinchinat, Ashley

AU - Gupta, Sumit

AU - Cooper, Stacy L.

AU - Rau, Rachel E.

PY - 2023/3

Y1 - 2023/3

N2 - Blinatumomab is a CD19 targeting bi-specific T-cell engager antibody construct developed for the treatment of CD19 expressing B-cell malignancies. Numerous adult and pediatric B-ALL clinical trials have demonstrated blinatumomab's efficacy in the relapse setting as well as in patients with residual disease after upfront chemotherapy. The safety profile of blinatumomab is also favorable, making it a feasible option for most patients. Several key questions remain, including the role of blinatumomab as a replacement for toxic elements of standard chemotherapy regimens in the upfront setting, its role as a bridge to hematopoietic stem cell transplantation, or whether previous blinatumomab impacts the efficacy of subsequent CAR-T cell therapy.

AB - Blinatumomab is a CD19 targeting bi-specific T-cell engager antibody construct developed for the treatment of CD19 expressing B-cell malignancies. Numerous adult and pediatric B-ALL clinical trials have demonstrated blinatumomab's efficacy in the relapse setting as well as in patients with residual disease after upfront chemotherapy. The safety profile of blinatumomab is also favorable, making it a feasible option for most patients. Several key questions remain, including the role of blinatumomab as a replacement for toxic elements of standard chemotherapy regimens in the upfront setting, its role as a bridge to hematopoietic stem cell transplantation, or whether previous blinatumomab impacts the efficacy of subsequent CAR-T cell therapy.

KW - B-ALL

KW - Immunotherapy

KW - Minimal residual disease

UR - http://www.scopus.com/inward/record.url?scp=85146458980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146458980&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2022.12.011

DO - 10.1016/j.clml.2022.12.011

M3 - Review article

C2 - 36642665

AN - SCOPUS:85146458980

SN - 2152-2650

VL - 23

SP - 159

EP - 167

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 3

ER -

SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this